Trial Profile
Alternating Targeted Therapy in Patients With Metastatic Renal Cell Carcinoma: A Phase II Study of Alternating Sunitinib and Temsirolimus
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 25 Sep 2023
Price :
$35
*
At a glance
- Drugs Sunitinib (Primary) ; Temsirolimus (Primary)
- Indications Renal cell carcinoma
- Focus Therapeutic Use
- 19 Sep 2023 Status changed from active, no longer recruiting to completed.
- 09 Aug 2022 Planned End Date changed from 1 Jun 2022 to 1 Oct 2022.
- 09 Aug 2022 Planned primary completion date changed from 1 Jun 2022 to 1 Oct 2022.